In the early 1990s, the US National Institute on Drug Abuse (NIDA) began the development of ibogaine as a prescription medicine by fully funding pre-clinical animal trials, and Phase 1 safety trials on human subjects. Unfortunately, further research was halted because of intellectual property litigation. Attempts to complete Phase 2 and 3 clinical trials are ongoing, but slowed by funding restrictions.
While there is a huge need for more research to be done, many supportive studies and observational assessments of ibogaine’s efficacy that have been published since the mid-1990s have continued to uphold early claims of of ibogaine’s safety and efficacy as a treatment for substance use disorder.
Support Ibogaine Research
Supporting GITA supports the development of ibogaine research, and helps to bridge the gaps between researchers and clinicians. Join us, if you support our mission to develop ibogaine and iboga as legally recognized medicines.
Research Projects in Development
GITA has partnered with the International Center for Ethnobotanical Education, Research and Service (ICEERS) in order to conduct two important research research projects.
Long Term Efficacy
In an ongoing, multi-site study, GITA members will collect information about long-term treatment outcomes from willing participants in order to compare efficacy of ibogaine treatment with conventional treatments and other modalities.
Ibogaine Experience Questionnaire
Current research measures used to study peak experience and psychedelic medicines tend to fail to capture the uniqueness of the ibogaine experience. GITA and ICEERS are working together to develop an ibogaine experience questionnaire to be used in future research.
GITA manages several data collection efforts that are used to benchmarking service standards, to increase the safety and efficacy of treatment, and to inform future research efforts.
IBO+Plus™ Observational Study
GITA collaborated with Canadian company Phytostan Neutriceuticals to enroll participants in an observational study designed to examine the effects of the company’s experimental multi-vitamin product, IBO+Plus™, which contains a sub-perceptual dose of ibogaine. Although GITA no longer assisting in enrolling new participants, we continues to assist with data collection for the study. Current participants can access the weekly questionnaire below.